

Marco Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5869158/publications.pdf>

Version: 2024-02-01

94
papers

4,163
citations

126708

33
h-index

110170

64
g-index

95
all docs

95
docs citations

95
times ranked

5797
citing authors

#	ARTICLE	IF	CITATIONS
1	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	2.5	19
2	Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232110630.	1.1	3
3	A Novel Bispecific T-Cell Engager (CD1a x CD3 μ) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells. <i>Cancers</i> , 2022, 14, 2886.	1.7	9
4	miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. <i>Leukemia</i> , 2021, 35, 823-834.	3.3	33
5	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
6	Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. <i>Frontiers in Oncology</i> , 2021, 11, 624405.	1.3	7
7	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 684638.	1.6	33
8	Enlarging the clinical spectrum of chorea-acanthocytosis. <i>Neurological Sciences</i> , 2021, 43, 1453.	0.9	1
9	A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. <i>Annals of Hematology</i> , 2020, 99, 331-341.	0.8	4
10	Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102911.	0.5	0
11	Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling. <i>ACS Omega</i> , 2020, 5, 30436-30443.	1.6	20
12	Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. <i>Non-coding RNA</i> , 2020, 6, 37.	1.3	10
13	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
14	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. <i>Haematologica</i> , 2020, 106, 185-195.	1.7	33
15	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <i>Cancers</i> , 2020, 12, 320.	1.7	24
16	Mycosis fungoides and gastric T α cell lymphoma: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 15.	0.4	1
17	miR-22 suppresses DNA ligase III addiction in multiple myeloma. <i>Leukemia</i> , 2019, 33, 487-498.	3.3	39
18	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. <i>Expert Review of Hematology</i> , 2019, 12, 665-684.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. <i>Cancers</i> , 2019, 11, 990.	1.7	47
20	Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 32.	6.9	28
21	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. <i>Cancers</i> , 2019, 11, 236.	1.7	35
22	FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e94.	0.2	1
23	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. <i>Blood</i> , 2019, 134, 4355-4355.	0.6	2
24	PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3107-3107.	0.6	0
25	Global Rnaseq/Proteomic-Phosphoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM. <i>Blood</i> , 2019, 134, 505-505.	0.6	0
26	A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells. <i>Blood</i> , 2019, 134, 4411-4411.	0.6	0
27	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. <i>Leukemia</i> , 2018, 32, 1948-1957.	3.3	179
28	MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. <i>Leukemia</i> , 2018, 32, 1003-1015.	3.3	51
29	Mouse models of multiple myeloma: technologic platforms and perspectives. <i>Oncotarget</i> , 2018, 9, 20119-20133.	0.8	35
30	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , 2018, 132, 1050-1063.	0.6	52
31	Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 230-234.	0.8	5
32	Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety. <i>Blood</i> , 2018, 132, 5869-5869.	0.6	1
33	Abstract 4431: Phosphoproteomic analysis of miR-21 modulation in Th17 cells: Potential implications for multiple myeloma bone disease therapy. , 2018, , .		0
34	Abstract 2827: Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma. , 2018, , .		0
35	Abstract 1783: UMG1, a novel humanized monoclonal antibody against a glycosylated-CD43-related epitope, induces antibody-dependent cellular cytotoxicity (ADCC) on human T-cell acute lymphoblastic leukemia cells. , 2018, , .		0
36	Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation. <i>Blood</i> , 2018, 132, 2449-2449.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Blood</i> , 2018, 132, 1418-1418.	0.6	1
38	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 1585-1585.	0.6	0
39	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. <i>Blood Advances</i> , 2017, 1, 455-466.	2.5	54
40	Abstract 2550: Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity. , 2017, , .		0
41	A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. <i>Blood Cancer Journal</i> , 2016, 6, e511-e511.	2.8	37
42	Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2016, 30, 2419-2422.	3.3	22
43	Mir-221/222 are promising targets for innovative anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1099-1108.	1.5	45
44	Abstract 1077: Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential. , 2016, , .		0
45	Multiple Myeloma in Patients with HCV-Related Disease:a Case Report. <i>Blood</i> , 2016, 128, 5700-5700.	0.6	0
46	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. <i>Oncotarget</i> , 2015, 6, 27343-27358.	0.8	89
47	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. <i>Leukemia</i> , 2015, 29, 2173-2183.	3.3	104
48	Multiple myeloma-related bone disease: state-of-art and next future treatments. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 33-47.	0.7	0
49	miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. <i>Oncotarget</i> , 2015, 6, 12837-12861.	0.8	112
50	MicroRNAs in multiple myeloma and related bone disease. <i>Annals of Translational Medicine</i> , 2015, 3, 334.	0.7	19
51	Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines. <i>Blood</i> , 2015, 126, 3019-3019.	0.6	0
52	A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations. <i>BioDrugs</i> , 2014, 28, 499-511.	2.2	13
53	In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells. <i>PLoS ONE</i> , 2014, 9, e89659.	1.1	77
54	Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1394-1396.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability. <i>Blood</i> , 2014, 124, 3417-3417.	0.6	2
56	MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 459-467.	0.9	46
57	MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2060-2060.	0.6	0
58	Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study. <i>Radiologia Medica</i> , 2013, 118, 930-948.	4.7	33
59	miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. <i>Journal of Cellular Physiology</i> , 2013, 228, 1506-1515.	2.0	156
60	Immunologic microenvironment and personalized treatment in multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S83-S93.	1.4	39
61	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2013, 49, 593-603.	1.3	106
62	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. <i>Cell Cycle</i> , 2013, 12, 3650-3662.	1.3	96
63	Targeting miR-21 Inhibits <i>In Vitro</i> and <i>In Vivo</i> Multiple Myeloma Cell Growth. <i>Clinical Cancer Research</i> , 2013, 19, 2096-2106.	3.2	195
64	Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor. <i>Blood</i> , 2013, 122, 124-124.	0.6	10
65	Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells. <i>Blood</i> , 2013, 122, 4451-4451.	0.6	1
66	From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario. <i>Current Drug Targets</i> , 2013, 14, 1144-1149.	1.0	45
67	Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease. <i>Blood</i> , 2013, 122, 683-683.	0.6	0
68	Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo. <i>Blood</i> , 2013, 122, 4489-4489.	0.6	0
69	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> Evidence. <i>Clinical Cancer Research</i> , 2012, 18, 6260-6270.	3.2	213
70	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. <i>Cell Death and Disease</i> , 2012, 3, e436-e436.	2.7	137
71	Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 838-846.	0.8	84
72	Molecular Targets for the Treatment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 757-767.	0.8	59

#	ARTICLE	IF	CITATIONS
73	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. <i>Blood</i> , 2012, 120, 5002-5013.	0.6	121
74	MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile.. <i>Blood</i> , 2012, 120, 2941-2941.	0.6	1
75	Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease. <i>Blood</i> , 2012, 120, 3960-3960.	0.6	0
76	A peroxisome proliferator-activated receptor gamma (<i>PPARG</i>) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. <i>British Journal of Haematology</i> , 2011, 154, 529-533.	1.2	69
77	A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. <i>Leukemia</i> , 2011, 25, 707-711.	3.3	93
78	Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <i>In Vitro</i> , Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 1984-1997.	3.2	67
79	Mir-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical <i>In Vitro</i> and <i>In Vivo</i> Evidence. <i>Blood</i> , 2011, 118, 2910-2910.	0.6	0
80	SCID-Synth-Hu: a Novel Multiple Myeloma Model for <i>In Vivo</i> Expansion of Primary Cells. <i>Blood</i> , 2010, 116, 452-452.	0.6	0
81	Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy. <i>Current Cancer Drug Targets</i> , 2009, 9, 854-870.	0.8	20
82	Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. <i>Blood</i> , 2009, 114, 555-563.	0.6	235
83	<i>In vivo</i> anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. <i>British Journal of Haematology</i> , 2008, 143, 520-531.	1.2	59
84	Regulatory T Cells Expanded by Autologous Mature Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase Are Potent Suppressors of T Cell Proliferation.. <i>Blood</i> , 2008, 112, 1553-1553.	0.6	0
85	Mature Conventional Human Dendritic Cells Express Indoleamine 2,3-Dioxygenase and Support the Relative Expansion of Autologous Regulatory T Cells.. <i>Blood</i> , 2007, 110, 1804-1804.	0.6	0
86	Modulation of Gene Expression Profile and <i>In Vivo</i> Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacetylase Inhibitor.. <i>Blood</i> , 2007, 110, 4790-4790.	0.6	0
87	Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?. <i>European Journal of Cancer</i> , 2006, 42, 1530-1538.	1.3	29
88	Dendritic cells have the option to express IDO-mediated suppression or not. <i>Blood</i> , 2005, 105, 2618-2618.	0.6	47
89	Role of nucleophosmin in embryonic development and tumorigenesis. <i>Nature</i> , 2005, 437, 147-153.	13.7	513
90	Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity. <i>Journal of Immunology</i> , 2005, 175, 1373-1381.	0.4	286

#	ARTICLE	IF	CITATIONS
91	Role of NPM in the Control of Genetic Stability and Tumorigenesis.. Blood, 2005, 106, 1595-1595.	0.6	0
92	Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. The Hematology Journal, 2003, 4, 346-350.	2.0	26
93	Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?. Human Immunology, 2002, 63, 1194-1200.	1.2	25
94	Emerging Role of MicroRNAs in the Pathophysiology of Immune System. , 0, , .		0